In-depth interviews were conducted with different stakeholders involved in or knowledgeable about the drug evaluation process in Spain: Clinicians (oncologists and neurologists), experts in health economics, hospital pharmacists, evaluation technicians, and hospital managers.

The current situation was understood: percentages and times for drug approval, prioritization of requirements for financing, and addressing financial and clinical uncertainty.

The perception of the future was identified: detection of drivers and barriers in the application of new drug approval models.

An analysis of different perceptions and differences of the stakeholders was made, combined with the variables object of the study: representation of Autonomous Communities, level of connection with the evaluation process, participation at the hospital, regional or national level and according to the organization’s evaluators.

Aspects such as: differences and nuances between the different stakeholders, evaluation criteria in different scenarios, approval percentages and times, ideal requirements for approval, and differences by profile of knowledge of the new model were analyzed.

The levers to activate to promote the new financing model based on results were detected, as well as to guarantee greater access to the most innovative medicines in Spain.

Opportunities and next steps were defined in relation to communication, consensus, technological infrastructure, innovative models, and human resources; thus, being able to implement the levers identified transversally and from different perspectives.